JP Morgan Chase’s Eupraxia Pharmaceuticals EPRX Stock Holding History

JP Morgan Chase’s Portfolio EPRX Stock Details EPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$93.5K	Buy	14,186 +13,613	+2,376%	+$93.9K	﹤0.01%	6104
2026 Q1	$3.79K	Buy	+573	New	+$4.61K	﹤0.01%	6925
2025 Q4	–	Sell	-16,467	Closed	-$97.2K	–	7849
2025 Q3	$97.2K	Sell	16,467 -2,250	-12%	-$12.2K	﹤0.01%	5919
2025 Q2	$108K	Buy	18,717 +16,017	+593%	+$61.5K	﹤0.01%	5569
2025 Q1	$8.86K	Buy	+2,700	New	+$9.32K	﹤0.01%	6332
2024 Q3	–	Sell	-1,892	Closed	-$4.88K	–	7736
2024 Q2	$4.88K	Buy	+1,892	New	+$5.26K	﹤0.01%	6389

Other funds holding EPRX

BGC

Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Jupiter Topco New York $245B AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

JP Morgan Chase's EPRX Position: Q2 2026 in Review

JP Morgan Chase increased its Eupraxia Pharmaceuticals (EPRX) stake by 2,376% in Q2 2026, buying an estimated $93.9K and bringing the position to 14,186 shares worth $93.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6104.

JP Morgan Chase first reported a position in EPRX in Q2 2024 and has held it in 6 quarters since. The position peaked at $108K in Q2 2025. 68 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

JP Morgan Chase held 14,186 shares of Eupraxia Pharmaceuticals worth $93.5K as of Q2 2026.
JP Morgan Chase bought 13,613 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $93.9K.
Eupraxia Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6104 holding.
JP Morgan Chase first reported a position in Eupraxia Pharmaceuticals in Q2 2024 and has held it in 6 quarters since.
JP Morgan Chase's Eupraxia Pharmaceuticals position peaked at $108K in Q2 2025.
68 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.